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Abstract 
 
Millions of women still use postmenopausal hormone therapy (HT). We genotyped 2090 women in Heart 
and Estrogen/progestin Replacement Study for functional polymorphisms in GP1BA and GP6 and assessed 
the coronary heart disease (CHD) event rate over 5.8 years of followup. In patients receiving placebo, there 
was an increased CHD death/myocardial infarction (MI)/unstable angina (UA) event rate in carriers of the 
GP1BA -5C allele (adjusted [adj] P = .006). HT increased the hazard ratio (HR) of CHD events in patients 
with the GP1BA -5TT genotype by 16% and reduced the HR in patients with the TC+CC genotypes by 
46% (adj interaction P < .001). HT reduced the HR in patients with the GP6 13254TT genotype by 17% 
but increased the HR in patients with the TC+CC genotypes by 35% (adj interaction P < .001). 
Furthermore, HT increased the HR of CHD events in patients with the GP1BA -5TT plus GP6 
13254TC+CC genotypes by 57% and reduced the HR in patients with the GP1BA -5TC+CC plus GP6 
13254TT genotypes by 55% (adj interaction P < .001). In postmenopausal women with established CHD, 
these polymorphisms of platelet genes were predictors of CHD events and significantly modified the 
effects of HT on CHD risk. It will be important to replicate these findings in other studies.  
 
Introduction 
 
Coronary heart disease (CHD) is the most common cause of morbidity and mortality 
among American men and women. Based on laboratory investigations and observational 
studies, it was previously believed that postmenopausal hormone therapy (HT) was 
cardioprotective.1 However, randomized clinical trials with HT have either failed to 
support this benefit or have demonstrated adverse coronary outcomes in women receiving 
HT.2-5 As a result, HT use in the United States has dramatically decreased, although 
millions of women still use these agents.6 Because of the continued use of HT and 
because the absolute risk of adverse cardiovascular events is rather small, it would be 
highly desirable to have markers of HT risk that would permit a more rational approach 
to patient management. 
 
Myocardial infarction (MI) and unstable angina (UA) develop when a platelet thrombus 
forms at the site of a ruptured or eroded unstable coronary atherosclerotic plaque.7 The 
essential pathophysiologic components of platelet thrombus formation are adhesion, 
activation, and aggregation. Two major platelet receptors involved in adhesion and 
activation are the von Willebrand factor receptor, glycoprotein (GP) IbE, and a major 
signaling collagen receptor, GPVI.8 Upon arterial plaque rupture, the initial platelet 
contact to exposed subendothelial collagen requires the binding of the platelet membrane 
GPIbE to immobilized von Willebrand factor (VWF).8 The VWF-GPIbE interaction 
results in platelets “rolling” along the exposed subendothelium, and this slower velocity 
permits platelet GPVI to bind to collagen.9 Signaling between and through these crucial 
adhesive receptors causes platelet activation and subsequent aggregation.  
 
Genetic contributions to CHD and arterial thrombosis are well established.10 The 
“Kozak” polymorphism of the gene encoding GPIbE (GP1BA) is a T>C substitution 5 
base pairs upstream of the initiation codon that has been associated with increased 
platelet expression of GPIbE and with acute coronary syndrome (ACS) risk in some 
studies,11-13 although other studies have found no association.14-16 The gene encoding 
GPVI (GP6) harbors a 13254T>C polymorphism that induces a Ser219Pro substitution; 
the 13254CC genotype has been associated with an increased risk of MI17 and coronary 
thrombi,18 despite being associated with less in vitro thrombogenicity on collagen.19 Most 
of the genetic epidemiology studies on GP1BA and GP6 polymorphisms have been 
exclusively or predominantly in male patients, despite the fact that some studies suggest 
that genetic effects on arterial thrombosis may be greater for women than men.20-22 
The Heart and Estrogen/progestin Replacement Study (HERS) was a large randomized 
clinical trial of HT in women with established coronary disease. Because HT use has 
been associated with increased platelet reactivity,23-26 we reasoned that the HERS trial 
provided a unique opportunity to test for (1) associations between inherited variations in 
platelet genes and CHD events, and (2) interactions between these platelet 
polymorphisms and HT in a population of women with established CHD. 
 
Patients, materials, and methods 
 
Study subjects 
 
The design, methods, and main outcomes of HERS have been previously reported.2,27 
Participants were postmenopausal women younger than 80 years with established 
coronary artery disease and no prior hysterectomy who were randomly assigned to oral 
conjugated equine estrogen (0.625 mg per day) plus medroxyprogesterone acetate (2.5 
mg per day) or placebo. The study was approved by an institutional review committee at 
each of the 18 US centers2 and the subjects gave informed consent. Established coronary 
disease was defined as 1 or more of the following: MI, coronary artery bypass graft 
surgery, percutaneous coronary revascularization, or angiographic evidence of at least a 
50% occlusion of 1 or more major coronary arteries. The clinical trial ended after 4.1 
years of follow-up, at which time the decision to use HT was left to the participant and 
her physician (details described in Grady et al.27). Outcome follow-up continued for an 
additional 2.7 years, for a mean total follow-up of 6.8 ± 2.0 years. 
 
Outcomes 
 
The outcome of interest for the current analysis is the composite of all CHD events 
including CHD death, nonfatal MI, and UA requiring hospitalization. These outcomes are 
all felt to be dependent, in some part, upon platelet thrombus formation. CHD death 
included a documented fatal MI, sudden death within 1 hour of onset of symptoms, 
unobserved death that occurred out of the hospital in the absence of other known causes, 
and death due to coronary revascularization or congestive heart failure. The diagnosis of 
nonfatal MI was based on an algorithm that included ischemic symptoms, 
electrocardiogram (ECG) abnormalities, and elevated cardiac enzyme levels.28 UA was 
diagnosed in participants who were admitted to the hospital for management of anginal 
chest pain or an anginal equivalent but found not to have an MI. Details concerning the 
documentation of clinical events are described elsewhere.28 
DNA isolation and genotyping 
 
At the end of the trial, consent was obtained from participants to use their annually 
collected pap smears as a source of DNA for future studies of the cardiovascular and 
other effects of estrogen. Consent was also requested from family members of deceased 
participants. After consent was obtained, coverslips were removed with a razor blade 
after placing the slides on a metal stage in a liquid nitrogen bath. Slides were then treated 
in consecutive washes of Citrisolv (Fisher Scientific, Sommeville, NY) (first for 10 
minutes, then for 5 minutes) to remove the coverslip adhesive followed by 2 washes in 
100% ethanol (first for 10 minutes, then for 5 minutes). Slides were then allowed to air-
dry. After the addition of  20 OL water, cellular material was scraped from the slides 
using a razor blade, transferred to a 1.5-mL microfuge tube, and resuspended in 600 OL
Cell Lysis Solution (Gentra Systems, Minneapolis, MN). The cell lysis was treated with 4 
OL proteinase K (20 mg/mL), followed by incubation at 55°C for at least 3 hours. Four 
microliters of RNaseA(Gentra Systems) was added to each tube, mixed by inverting, and 
incubated at 37°C for 15 minutes. Next, 200 OL Protein Precipitation Solution (Gentra 
Systems) was added and mixed by vortexing for 20 seconds. The proteins were pelleted 
by centrifugation (13 000g to 16 000g) for 3 minutes, and the supernatant was transferred 
to a 1.5-mL microfuge tube. After the addition of 2.0 OL Gentra Glycogen solution (20 
Og/mL), the DNA was precipitated with isopropanol and washed with 70% ethanol. Each 
sample was resuspended in 20 OL DNA Hydration solution (Gentra Systems), rehydrated 
at 60°C for 1 hour, quantified, and stored at -20°C.  
 
Genotyping of the GP1BA -5T>C and GP6 13254T>C single-nucleotide polymorphisms 
(SNPs) was performed using the MassARRAY genotyping system (Sequenom, San 
Diego, CA). For GP1BA -5T>C, the polymerase chain reaction (PCR) primers 5’-
ACGTTGGATGTTGGCAGCAGGAGCAGCAAG-3’ and 5’-
ACGTTGGATGATCCACTCAAGGCTCCCTTGC-3’ were used in conjunction with the 
extension primer 5’- GAGGAGGAGAGGCATGAGG-3’. For GP6 13254T>C, the PCR 
primers 5’-ACGTTGGATGATGGACCCTGCAGAACCTAC-3’ and 5’-
CGTTGGATGTCTGATTTCCCAGGAACCTC-3’ were used with the extension primer 
5’-AGAACCTACCTGCTACCG-3’. All reactions were performed according to the 
manufacturer’s instructions, and scoring was performed using SpectroTyper software 
(Sequenom). Consent and usable DNA were obtained from 2229 of the original 2763 
HERS participants (81%). From these subjects, 2090 (94%) were successfully genotyped 
for both the GP1BA variant and the GP6 variant. Analyses for the current report are 
based on data from this subset of the original HERS cohort. Participants were also 
genotyped for 5 other genetic variants in platelet genes: the PlA (HPA-1, Leu33Pro) 
polymorphism of ITGB3, a second variant in GP1BA (HPA-2, GPIbE Thr145Met), the 
807T>C polymorphism of ITGA2, the1838G>A substitution of ADRA2A (E2-adrenergic 
receptor), and the 852C>T substitution of GNB3 (beta subunit of G proteins). None of 
these other 5 SNPs consistently interacted with HT at year 1 and follow-up (Tables S1-S3 
available on the Blood website; see the Supplemental Tables link at the top of the online 
article). 
 
Statistical analyses 
 
Chi-square tests were used to test for Hardy-Weinberg equilibrium for each SNP after 
stratification by race/ethnicity. Cox proportional hazard models were used to estimate 
genotypic relative hazards in the placebo group after adjustment for age and potentially 
confounding baseline covariates. These baseline covariates were identified using a 
forward stepwise selection process from among all the variables listed in Table 1 that 
were associated (P < .1) with case status in univariate analyses. The variables that 
survived the forward stepwise selection process at a level of P < .05 included 
hypertension based on physician diagnosis or blood pressure higher than 140/90 mm Hg, 
diabetes requiring medication, creatinine clearance, waist-to-hip ratio, and aspirin and 
statin use. The addition of other variables reasonably predicted to influence the outcomes 
of interest based on a priori knowledge, but not included in the stepwise selection 
process, including race and smoking, did not change the qualitative result (data not 
shown). In separate analyses, the addition of each of the baseline covariates, including all 
of those retained in the stepwise procedure, was evaluated for its potential effect on the 
genotypic hazard ratios; however, none of them materially changed the magnitude or the 
significance of the univariate association between the genotypes of interest and risk for 
CHD events. Data on nonsteroidal anti-inflammatory and COX-2 inhibitor use were not 
available. The genetic associations were examined using both additive and dominant 
genetic models. There were too few variant allele homozygotes to support recessive 
models. Haplotype analyses were performed using Haplo.GLM (SAS, Cary, NC). To 
assess the possibility of an interaction between the platelet receptor protein 
polymorphisms and HT, additional Cox models were constructed using the entire study 
population. These models included treatment assignment, gene polymorphism, and 
treatment assignment*gene polymorphism interaction terms. The likelihood ratio test was 
used to assess the significance of the interactions. The interaction analyses assumed a 
dominant genetic model for each allelic variant and were performed according to 
intention to treat. Relative hazards for the composite outcome were determined based on 
CHD events that occurred after 1 year of follow-up as well as all CHD events that 
occurred prior to closeout. The year-1 results were evaluated because of a previously 
documented pattern of excess risk during the first year in the HT group. Additional 
analyses were performed after stratification of cases as MI/CHD deaths or UA. In 
general, the results produced similar patterns to that observed with all cases, although 
with less power and statistical significance than with the combined cases (data not 
shown). All analyses were performed using SAS version 9.1. 
 
Results 
 
Patient characteristics 
 
Two thousand ninety (76%) of the original 2763 HERS subjects were successfully 
genotyped for both the GP1BA -5T>C and the GP6 13254T>C variants. These subjects 
were followed for a mean ±SD of 5.8 ± 2.0 years. During that time, 526 women (25%) 
suffered a CHD event (non-fatal MIs, 248; CHD deaths, 77; hospitalizations for UA, 
201). The baseline characteristics of the study population, stratified by the presence or 
absence of a CHD event at any time during follow-up, are shown in Table 1. There were 
no significant differences between the subjects included in this report and the remainder 
of the cohort with respect to the characteristics included in Table 1 (data not shown). As 
expected, women who suffered a CHD event had more traditional cardiovascular risk 
factors than those who did not have events. However, there were no significant 
differences between the cases and noncases for baseline low-density lipoprotein (LDL) or 
high density lipoprotein (HDL) cholesterol levels. After stratification for race, the platelet 
gene variants were in Hardy-Weinberg equilibrium in all 3 racial categories except for 
the GP6 variant in African Americans (P = .01; Table 2; Table S1). 
 
Platelet receptor genotypes and risk for CHD 
 
In analyses limited to the placebo group, carriers of 1 or 2 copies of the GP1BA -5C allele 
had higher rates of CHD events than T-allele homozygotes (Table 3). In adjusted models, 
assuming an additive genetic effect, the data provided modest evidence of an association 
at 1 year and strong evidence of an association after 5.8 years of follow-up. Dominant 
models produced comparable evidence of association (year 1: hazard ratio [HR] 1.68, 
95% confidence interval [CI] 0.93-3.01, P = .090; closeout: HR 1.35, 95% CI 1.04-1.76, 
P = .026). The probability of a false-positive report for the dominant-model association 
between the GP1BA -5C allele and CHD events is less than 25%, assuming a true odds 
ratio (OR) of at least 1.5 and a prior probability of at least 10%.29 Models limited to 
white women produced a similar pattern of results (additive models, year 1: P = .09;
closeout: P = .001). Haplotype analyses for the 3 common (> 5%) haplotypes defined by 
the -5C>T and the Met145thr SNPs showed that the only common haplotype containing 
the -5C allele was also associated with CHD events in the entire cohort after adjustment 
for race and covariates (year-1 OR = 1.6, P = .07; closeout OR = 1.4, P = .01) and in 
similar analyses restricted to white individuals only (year-1 OR = 2.0, P = .01; closeout 
OR = 1.3, P = .07). There were too few events in African Americans and other ethnicities 
to evaluate separately. 
 
Conversely, there was no convincing evidence of an association between the GP6 13254
variant and risk for CHD events at either time point using additive (Table 3) or dominant 
models or in analyses limited to the white-only sample (data not shown). At 1 year, the 
ADRA2A SNP was associated with CHD events, but this relationship did not persist upon 
follow-up (Table S2). None of the other 4 platelet gene SNPs was associated with CHD 
events (Table S2). 
 
Effect of HT on CHD events according to platelet receptor genotypes 
 
Carriers of the common GP1BA -5TT genotype assigned to receive HT had more events 
during the first year than GP1BA -5TT women assigned to receive placebo (HR = 1.62, 
95% CI 1.03-2.55; Table 4). This increased risk was attenuated after 5.8 years of follow-
up (HR = 1.16, 95% CI 0.95-1.41; Table 4). In contrast, women with the less common -
5TC and -5CC GP1BA genotypes assigned HT had fewer CHD events than similar 
women that received placebo, an effect that was evident at both 1 and 5.8 years of follow-
up. This pattern of excess or neutral CHD risk with HT in GP1BA -5TT women and 
reduced risk in GP1BA -5TC or CC women produced evidence of a drug*gene 
interaction at both time points (P < .001 for both). When analyses were limited to white 
individuals only, the evidence of interaction remained (P = .002 and .001, respectively). 
 
Although the GP6 genotypes were not associated with CHD events in patients 
randomized to placebo (Table 3), there was modest evidence of interaction with treatment 
assignment. Women assigned to receive HT who were GP6 T-allele homozygotes had 
lower rates of CHD, whereas similarly treated women who were carriers of the C allele 
had higher rates of CHD when compared with women taking placebo (test for interaction, 
year 1: P < .001; closeout: P < .001; Table 4). The same pattern was also evident in the 
white-only sample (P for interaction, year 1: .046; closeout: .008). None of the other 5 
platelet gene SNPs interacted with HT for CHD events (Table S3). 
 
Gene-gene and gene–gene-HT interactions 
 
In light of the results from the individual loci, we also considered whether combinations 
of genotypes would impart a greater or lesser risk for CHD events, with and without HT. 
Classifying women taking placebo according to carriership for the variant (C) alleles for 
the 2 platelet receptor polymorphisms defined 4 groups (Table 5). In women assigned to 
receive placebo, carriers of the GP1BA -5C allele who were also homozygous for the 
GP6 T allele (group 3, n = 168, 16% of the study population) had a higher rate of CHD 
events than the other 3 groups; however, there was only marginal evidence of 
heterogeneity across the 4 groups (year 1: P = .07; closeout: P = .04) and the formal test 
of a GP1BA * GP6 interaction was not significant (year 1: P = .38; closeout: P = .51). 
 
In contrast, the effect of HT varied considerably across the 4 groups (Table 6). Women 
with the -5TT GP1BA genotype who were also carriers of the GP6 C allele (group 2, n = 
443, 21%) had significantly greater risk for CHD events with HT, whereas women who 
were carriers for the GP1BA -5C allele and homozygous for the GP6 T allele (group 3, n 
= 351, 17%) experienced dramatic reductions in risk (Table 6; Figure 1). These data 
provided evidence for a genotype group * HT interaction at both 1 year and closeout (P =
.004 and P < .001, respectively). 
 
Discussion 
 
Data from the Women’s Health Initiative indicate that estrogen plus progesterone HT 
increases MI and stroke despite its beneficial effects on cholesterol levels. Since blood 
platelets play a central role in the pathophysiology of MI and stroke, we hypothesized 
that certain inherited variations in platelet genes could be associated with CHD outcomes 
and that the prothrombotic effects of HT are modified by such genetic variants. This 
latter possibility could lead to HT being a risk factor for CHD events in some, but not all, 
postmenopausal women. The data from the current study indicate that the -5T>C 
polymorphism in GP1BA is associated with increased risk for CHD events in women 
with established coronary disease and that both the-5T>C polymorphism in GP1BA and 
the 13254T>C polymorphism in GP6 modify the effect of HT on risk for CHD events. 
Specifically, in the 21% of women with the detrimental genotypes for both genes (Table 6 
group 2), HT was associated with a 6% absolute increase in risk for CHD events 
compared with placebo. Conversely, women with the complementary genotypes for both 
loci (Table 6 group 3) experienced roughly a 5% absolute risk reduction with HT. If our 
findings can be replicated in other studies, these HT pharmacogenetic findings may 
permit more individualized HT treatment decisions for women suffering from significant 
menopausal symptoms. 
 
Only one of the platelet polymorphisms we examined was a risk for CHD events in the 
placebo-treated group. Patients expressing the -5C “Kozak” polymorphism of GP1BA 
were at increased risk for recurrent CHD events (Table 3). Previous studies have been 
inconsistent in their findings regarding an association between this polymorphism and a 
heterogeneous group of CHD phenotypes, although the -5C allele has consistently been 
found to be associated with stroke (reviewed in Yee and Bray30). Previous studies on the 
association of the -5C SNP of GP1BA with ACSs differed with respect to design, number 
of cases, sex composition of the subjects, age of the subjects, and even the measured end 
point. The 3 studies that found no significant association between -5C and ACSs were 
small and cross-sectional.14-16 Perhaps more weight regarding the importance of the -
5T>C alleles should be given to the 2 studies that found an association because they were 
large and prospective,12,13 similar to HERS. 
 
We did not observe a significant relationship between the GP6 13254T>C polymorphism 
and CHD events, consistent with a report in the Japanese population31 and with findings 
showing that homozygosity for the 13254C (uncommon) allele was associated with 
reduced GPVI receptors and a reduced thrombogenicity on collagen.19,32 Although the 
GP6 13254T>C polymorphism changes an amino acid (Ser219Pro), there is no evidence 
that this substitution causes any reported functional alteration. Of note, Croft et al.17 
found that the GP6 13254CC genotype was associated with MI in women but not men. 
However, hormone use was not considered as a confounder, and perhaps the apparent sex 
difference was due to female hormone use. 
 
In the HERS population, each platelet polymorphism interacted individually (Table 4) 
and together (Table 6) with HT to modify the risk for CHD events. HT has been shown to 
interact with polymorphisms in other genes to modify risk for a variety of clinical events. 
For example, HT is associated with an increased risk of venous thromboembolic events in 
women with the factor V Leiden polymorphism33 and an increased risk of MI among 
hypertensive postmenopausal women with the prothrombin 20210G>A polymorphism.34 
HT has also been shown to interact with polymorphisms of estrogen receptor (ER)E for 
HDL levels 35 and for osteoporosis.36 In the Framingham Heart Study, HT was associated 
with increased platelet reactivity.26 However, our study is the first to examine the 
relationship between inherited platelet variations and HT for a CHD clinical end point.  
When we examined the interaction of the 2 modifying alleles with HT, we found that HT 
showed no increased risk for CHD/MI/UA for approximately 62% of the women in this 
study (Table 6; Figure 1A,D). However, those women with the GP1BA TT and GP6 TC 
or GP6 CC genotypes randomized to HT had a significantly increased risk of events 
(Table 6; Figure 1B). Conversely, we found 1 genotype combination (GP6 TT and 
GP1BA TC or CC) that was associated with lower rates of CHD with HT use. 
Considering the myriad of genetic and environmental factors that coalesce into the 
overall CHD risk for any 1 subject, it is not surprising that some genetic variants interact 
with HT in a beneficial manner and others in an adverse manner. As has been reported 
for the main findings of the entire HERS trial, the sum total of all factors interacting with 
HT indicates that HT is no benefit in this population. It should be noted that many of the 
effects of these platelet genes seen at 1 year were lessened by the end of the follow-up 
period (Tables 3-6). The effects of HT on platelet function have been reported to be 
maximal at 1 and 3 months and reduced or lost at 6 months,37 which would be consistent 
with a more prominent role for platelets in the early adverse CHD effects of HT in 
HERS.2 However, for those genotype combinations that had significant interactions, the 
curves separated in the first year, and a clear difference persisted throughout the follow-
up years. 
 
There are several potential mechanisms for the observed associations of the platelet 
polymorphisms with CHD events. The -5C allele of GP1BA has been associated with 
increased surface expression of GPIbE on platelets and increased adhesion to collagen 
under medium flow rates.11,38 In contrast, the 13254C allele of GP6 has been associated 
with decreased GPVI receptors and a reduced thrombogenicity on collagen,19,32 which 
would be consistent with our findings in Table 3. 
 
The relationship between HT and these genetic variations is less clear. We have shown 
that human megakaryocytes and platelets express ERE and ERß,39,40 raising the 
possibility that there is a direct hormonal effect on this cell lineage. We observed no 
change in GPIbE expression in ovariectomized mice treated with oral conjugated equine 
estrogen (CEE).41 However, oral CEE does increase platelet GPVI expression41 and the 
GP6 genotype affects receptor levels,19 although no study has directly assessed whether 
the genotype effect is modified by hormones. Because the 13256T>C SNP of GP6 
defines 2 haplotypes that have altered amino acids, it is possible that HT alters expression 
of another gene that interacts with platelets in a manner affected by the GPVI isoform 
that is expressed. In addition, because GPIbE and GPVI can physically associate in the 
platelet membrane,42 perhaps this association is favored with 1 GPVI isoform. 
 
Genetic association studies may suffer from bias due to population variations in allele 
frequency and linkage disequilibrium (LD).43 In the current study we found similar 
patterns of association and interaction after excluding African Americans; however, we 
are unable to rule out more subtle forms of population stratification within the white 
subset. Bias related to population variations in LD is less likely to be an issue for 
functional variants altering regulatory regions or coding sequences such as the ones 
included in this study. Genetic subgroup analyses are also susceptible to type I error. It is 
important to remember that exceptionally small P values, such as the one found in Table 
4, may still represent false-positive results, especially if the prior probability of the 
finding is low. The fact that there are biologically attractive mechanisms that are 
consistent with our data does not greatly diminish the need to interpret these findings 
with caution. It is also important to recognize that the women in this study all had 
established coronary disease. Whether or not similar findings might occur in younger 
healthier women, the magnitude of the effect, if present, remains to be established. The 
distribution of GP6 genotypes was out of Hardy-Weinberg in African Americans but not 
in white individuals. While we cannot rule out a genotyping error in the African 
Americans, the departure from Hardy-Weinberg is modest, the percentage of the cohort 
that is African American is small, and the results for the total cohort are similar to results 
from analyses restricted to white individuals only. There were too few African Americans 
with the GP6 variant allele to explore other possible explanations or to rule out the play 
of chance with a high degree of confidence. Despite these limitations, the dramatic nature 
of some of the interactions presented here, coupled with frequency of the allelic variants 
in question and the number of women contemplating HT use, suggest that these 
associations and interactions warrant further study at both the clinical and molecular 
level. 
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Tables and Figures 
 
Table 1.  Baseline characteristics of study population by case status 
_____________________________________________________________________________ 
Risk factor     Controls, n = 1564   Cases, n = 526   P
_____________________________________________________________________________ 
Demographic characteristics 
Mean age at randomization ± SD, y   66.3 ± 6.64  67.2 ± 6.53   .006 
Ethnicity, %           .14 
 African American     5.75   8.17    — 
 White      91.4   88.8    — 
 Other nonwhite     2.88   3.04    — 
 
Health-related behaviors, % 
Currently smoking     11.9   13.1    .46 
Any alcohol consumption    42.7   36.9    .02 
Exercise*      40.6   36.1    .06 
 
Medical conditions, % 
Diabetes†      18.4   30.3    < .001 
Receiving insulin or oral hypoglycemic agents  14.1   27.0    < .001 
At least 2 previous MIs     4.6   6.08    .18 
Previous PTCA     44.6   44.3    .89 
 
Physical examination 
Mean BMI ±SD, kg/m2 28.5 ± 5.44  28.8 ± 5.37   .36 
Mean waist-to-hip ratio, ±SD    0.87 ± 0.08  0.88 ± 0.08   .004 
High blood pressure, %‡    56.7   63.9    .004 
History or symptoms of CHF, %    10.2   14.8    .004 
 
Laboratory results 
Mean LDL cholesterol level ±SD, mg/dL   144.1 ± 37.7  146.3 ± 38.3   .25 
Mean HDL cholesterol level ±SD, mg/dL  50.6 ± 13.1  49.7 ± 12.7   .17 
Mean triglyceride level ±SD, mg/dL   165.4 ± 63.3  170.2 ± 63.8   .13 
Creatinine clearance, mL/min    62.4 ± 19.1  59.9 ± 19.6   .009 
 
Concomitant medication, % 
Aspirin use      81.7   77.4    .02 
Statin use      39.2   34.0    .03 
_____________________________________________________________________________ 
To convert LDL and HDL cholesterol levels from milligrams per deciliter to millimoles per liter, 
multiply each level by 0.02586. To convert triglyceride level from milligrams per deciliter to 
millimoles per liter, multiply triglyceride level by 0.01129. To convert creatinine clearance from 
mililiters per minute to milliliters per second, divide milliliters per minute by 60. 
 
—indicates not applicable; MI, myocardial infarction; PTCA, percutaneous transluminal coronary 
angioplasty; BMI, body mass index; and CHF, congestive heart failure. 
 
*Defined as regular participation in an exercise program or walking for at least 10 minutes per 
day. 
†Diabetes is defined as women reporting a history of diagnosis but no medication use and 
women with fasting plasma glucose levels greater than 6.94 mM (_ 125 mg/dL). 
‡High blood pressure is defined as systolic blood pressure of at least 140 mm Hg or diastolic 
blood pressure of at least 90 mm Hg. 
 
Table 2.  Allele and genotype frequencies 
_____________________________________________________________________________ 
 White individuals, n=1896 African Americans, n=133 Others, n=61*
_____________________________________________________________________________ 
GP1BA -5T>C 
 Alleles, n (%) 
 T 1650 (0.87)   106 (0.80)   48 (0.78) 
 C 246 (0.13)     27 (0.20)   13 (0.22) 
 Genotypes, n (%) 
 TT     1460 (0.77)   88 (0.66)   38 (0.62) 
 TC       417 (0.22)   37 (0.28)   13 (0.22) 
 CC        19 (0.01)     8 (0.06)     4 (0.07) 
 
GP6 13254T>C 
 Alleles, n (%) 
 T 1593 (0.84)   104 (0.78)   59 (0.96) 
 C 303 (0.16)     29 (0.22)     2 (0.04) 
 Genotypes, n (%) 
 TT     1346 (0.71)   86 (0.65)   56 (0.92) 
 TC       512 (0.27)   35 (0.26)     5 (0.08) 
 CC        38 (0.02)   12 (0.09)     0 (0) 
_____________________________________________________________________________
P values for E2 test of Hardy-Weinberg equilibrium all > .05 except for GP6 in African Americans 
(P = .01). 
*Hispanic (n = 17), Asian/Pacific Islander (n = 36), Native American (n = 6), unknown (n = 2). 
Table 3.  CHD events in women taking placebo according to GP1BA and GP6 
polymorphisms 
_________________________________________________________________________________ 
 Year 1     End of follow-up 
 -------------------------------------------------------------     -------------------------------------------------------------------- 
 n Cases, n  Rate*  HR (CI)†            P† Cases, n         Rate*        HR (CI)†           P†
_____________________________________________________________________________________________________ 
 
GP1BA -5T>C              .085                  .006 
 TT                789  32         41.3  1.00                         186  40.37  1.00   — 
 TC                 233  15 66.5  1.64 (0.88-3.05)                68  51.52  1.27 (0.96-1.68)  — 
 CC                   25   2  84.1  2.03 (0.47-8.65)                12  107.42  2.25 (1.25-4.06)  — 
 
GP6 13254T>C . 146                   .20 
 TT                 725 38  53.8  1.00                193  46.47  1.00   — 
 TC                 289 10 35.17  0.58 (0.28-1.2)                 65  38.48  0.82 (0.62-1.09)  — 
 CC    33    1  30.57  0.74 (0.27-2.0)   8  40.69  0.91 (0.64-1.3)  — 
_____________________________________________________________________________________________________ 
—indicates not applicable. 
*Expressed as n/1000/y. 
†Additive model adjusted for age, race, hypertension, diabetes, creatinine clearance, waist-to-hip ratio, aspirin use, and statin use at 
baseline. 
 
Table 4.  Interaction between HT and GP1BA –5T>C and HT and GP6 13254T>C genotypes for CHD 
___________________________________________________________________________________________________ 
 Year 1     End of follow-up 
 ---------------------------------------------------------------------------------------------------------------------------------- 
 Rx  n         Cases, n  Rate*  HR (CI)†            P† Cases, n         Rate*        HR (CI)†            P†
___________________________________________________________________________________________________ 
 
GP1BA              < .001                 < .001 
 TT       P       789           32            41.3      1.62 (1.03-2.55)      —               186              40.37       1.16 (0.95-1.41)      — 
 TT       HT     790          49            64.23               —                  —               211              46.55                  —                — 
 TC/CC     P        258          17            68.2      0.458 (0.2-1.07)       —                 80              55.89       0.54 (0.38-0.78)     — 
 TC/CC     HT      253           9             36.2                —                   —                 49              31.8                   —                — 
 
GP6               < .001                 < .001 
 TT            P        725         38            53.8       0.88 (0.56-1.41)       —               193              46.47       0.84 (0.68-1.03)    — 
 TT            HT      762         35            47.3                —                    —              176               39.3                   —                — 
 TC/CC      P        322         11            34.7       2.76 (1.31-5.84)       —                73               38.7        1.35 (0.98-1.85)     — 
 TC/CC      HT      281         23            84.8               —                    —                 84               52.66                 —               — 
____________________________________________________________________________________________________ 
Rx indicates treatment with placebo (P) or hormone therapy (HT); —, not applicable. 
*Expressed as n/1000/y. 
†Hazard ratios and confidence interval for effect of HT after adjustment for age, race, hypertension, diabetes, creatinine clearance, 
waist-to-hip ratio, and aspirin and statin use at baseline. 
‡P value for HT*genotype interaction after adjustment for age, race, hypertension, diabetes, creatinine clearance, waist-to-hip ratio, 
and aspirin and statin use at baseline. 
 
Table 5.  CHD events in women taking placebo according to combinations of GP1BA and GP6 genotypes 
______________________________________________________________________________________________________ 
 Patient genotype                               Year 1                                                     End of follow-up 
Patient      ------------------------            ---------------------------------------------------------      ----------------------------------------------------------- 
 Group       GP1BA       GP6 n Cases, n   Rate*            HR (CI)†         P‡ Cases, n   Rate*         HR (CI)†             P‡
______________________________________________________________________________________________________ 
 
1 TT           TT        557      24         44.0              1                     .071         137        42.3              1                     .043 
 2 TT        TC/CC    232        8          35.02     0.706 (0.30-1.64)    —            49        35.88    0.859 (0.62-1.20)    — 
 3 TC/CC        TT        168      14          87.14     2.016 (1.04-3.92)    —            56        61.44    1.461 (1.07-2.0)      — 
 4 TC/CC      TC/CC      90       3          33.88      0.73 (0.22-2.43)     —             24       46.23    1.032 (0.67-1.60)     — 
______________________________________________________________________________________________________ 
—indicates not applicable. 
*Expressed as n/1000/y. 
†Hazard ratios and confidence interval for effect of HT after adjustment for age, race, hypertension, diabetes, creatinine clearance, 
waist-to-hip ratio, and aspirin and statin use at baseline. 
‡Test for heterogeneity across all 4 genotype combination groups after adjustment for age, race, hypertension, diabetes, creatinine 
clearance, waist-to-hip ratio, and aspirin and statin use at baseline. 
 
Table 6. Interaction of HT with combination of GP1BA and GP6 genotypes for CHD risk 
____________________________________________________________________________________ 
 Patient           Patient genotype                               Year 1                                                     End of follow-up 
 group              -----------------------            ---------------------------------------------------------      ---------------------------------------------------------- 
 by HT               GP1BA       GP6 n No.         Rate*        HR (CI)†         P‡ No.        Rate*         HR (CI)†             P‡
______________________________________________________________________________________________________ 
Group 1                 TT             TT               1.257 (0.73-2.17) .004                       1.02 (0.81-1.30)     < .001 
 N 557    24         44.0              —               —               137         42.3                —                   — 
 Y 579    29        51.74             —               —               144         42.8                —                   — 
 
Group 2  TT         TC/CC                                    3.35 (1.4-8.03)     —                                        1.57 (1.08-2.29)          — 
 N 232      8        35.02             —               —                 49         35.88              —                   — 
 Y 211    20         98.81            —               —                 67           57.4              —                   — 
 
Group 3              TC/CC          TT                                       0.3 (0.11-0.92)     —                                        0.45 (0.28-0.70)          — 
 N 168     14       87.14            —               —                  56           61.44            —                   — 
 Y 183      6        33.39           —               —                  32           28.77             —                  — 
 
Group 4               TC/CC      TC/CC                                  1.37 (0.26-7.35)     —                                       0.76 (0.4-1.44)            — 
 N 90       3       33.88           —                 —                 24           46.23            —                  — 
 Y 70       3       43.59           —                 —                 17           39.84            —                  — 
________________________________________________________________________________________________________ 
—indicates not applicable. 
*Expressed as n/1000/y. 
†Hazard ratios and confidence interval for effect of HT after adjustment for age, race, hypertension, diabetes, creatinine clearance, 
waist-to-hip ratio, and aspirin and statin use at baseline. 
‡P value for HT*genotype interaction after adjustment for age, race, hypertension, diabetes, creatinine clearance, waist-to-hip ratio, 
and aspirin and statin use at baseline. 
 
Figure 1. Kaplan-Meier estimates of the cumulative incidence of primary end points by 
time to occurrence. The combined primary end point of cardiovascular death, nonfatal MI, or 
unstable angina is shown on the y-axis. Patients were grouped by treatment assignment and 
genotypes. The number of subjects (and percentage of total) with each genotype is shown. 
 
